Vudalimab (Anti-CTLA4 & PD-1)

製品コード：A4066        

印刷

Vudalimab is a bispecific antibody targeting PD-1 and CTLA-4 to inhibit immune checkpoint regulation and enhance immune responses. It is being developed for the treatment of advanced malignancies by promoting T-cell activation against tumors and metastatic castration-resistant prostate cancer (mCRPC). M.W 125.43 kDa

製品説明

CAS No. 2329669-72-7
Source CHO
Storage
(From the date of receipt)		 -80℃(avoid freeze-thaw cycles)
Shipping Shipped under low temperature conditions

人間や獣医の診断であるか治療的な使用のためにでない。